Developments in Post-marketing Comparative Effectiveness Research
- 6 June 2007
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 82 (2), 143-156
- https://doi.org/10.1038/sj.clpt.6100249
Abstract
Physicians and insurers need to weigh the effectiveness of new drugs against existing therapeutics in routine care to make decisions about treatment and formularies. Because Food and Drug Administration (FDA) approval of most new drugs requires demonstrating efficacy and safety against placebo, there is limited interest by manufacturers in conducting such head‐to‐head trials. Comparative effectiveness research seeks to provide head‐to‐head comparisons of treatment outcomes in routine care. Health‐care utilization databases record drug use and selected health outcomes for large populations in a timely way and reflect routine care, and therefore may be the preferred data source for comparative effectiveness research. Confounding caused by selective prescribing based on indication, severity, and prognosis threatens the validity of non‐randomized database studies that often have limited details on clinical information. Several recent developments may bring the field closer to acceptable validity, including approaches that exploit the concepts of proxy variables using high‐dimensional propensity scores, within‐patient variation of drug exposure using crossover designs, and between‐provider variation in prescribing preference using instrumental variable (IV) analyses. Clinical Pharmacology & Therapeutics (2007) 82 143–156. doi:10.1038/sj.clpt.6100249; published online 6 June 2007Keywords
This publication has 84 references indexed in Scilit:
- Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial ResultsMedical Care, 2007
- Understanding secondary databases: a commentary on “Sources of bias for health state characteristics in secondary databases”Journal of Clinical Epidemiology, 2007
- Reference drug programs: Effectiveness and policy implicationsHealth Policy, 2007
- Performance of Propensity Score Calibration--A Simulation StudyAmerican Journal of Epidemiology, 2007
- Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorizationBritish Journal of Clinical Pharmacology, 2006
- A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methodsJournal of Clinical Epidemiology, 2006
- Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental VariableEpidemiology, 2006
- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeuticsPharmacoepidemiology and Drug Safety, 2006
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983